Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Patients with atopic dermatitis (AD) treated with dupilumab may face a slightly elevated risk of developing psoriasis, with new study data showing a cumulative 3-year incidence of 2.86% compared ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Bio-Thera Solutions and SteinCares have signed a new agreement to commercialize a proposed biosimilar of dupilumab across ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...

Dupilumab, administered by subcutaneous injection, is the first targeted treatment to be approved in the United States for bullous pemphigoid, according to the company’s press release.